Medizone International Continues Board of Directors Expansion to Support Executing on the Launch of AsepticSure in Key Global Markets

New Medizone Board member Steve Meyer will add significant commercial experience to deliver on the company’s growth plans

 

KALAMAZOO, Mich., May 22, 2017 /PRNewswire/ — Medizone International, Inc. (OTCQB: MZEI) announces the appointment of Steve Meyer to the Board of Directors. Medizone makes this move in support of expanding the commercial experience of the team and to accelerate the growth of AsepticSure® in key markets across the globe.

“We continue to look for talented executives with significant commercial experience to help guide Medizone International as we work to deliver on our growth plans and reach our full potential in the market,” commented David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “As we execute on our commercial plans to establish the AsepticSure system as the new gold standard for disinfection across a wide range of commercial applications, we are pleased to announce that Steve Meyer has joined our Board of Directors. Steve brings a wealth of commercial experience and proven strong leadership to our team.”

Most recently, Steve was President, Chief Executive Officer and Director of Welch Allyn, Inc., a privately-held developer, manufacturer, and marketer of frontline care medical devices and diagnostic solutions headquartered in Skaneateles Falls, New York. Steve began his career at Welch Allyn as a sales representative over 30 years ago and built a successful career in global sales and marketing, product development and commercial strategy roles. As President and CEO, Steve navigated Welch Allyn during a time of substantial industry change, developing and executing a new strategy, restructuring the business, engaging more deeply with customers, and becoming more acquisitive. In September of 2015, Welch Allyn merged its business with Hill-Rom, Inc.

Steve is a native of Michigan and holds a Bachelor of Science in Biology from Alma College. He earned his Master of Business Administration from the William E. Simon Graduate School of Business at the University of Rochester, New York.

“I am very excited to join the Board of Directors of Medizone International as we execute on our commercial strategy,” commented Steve Meyer. “The AsepticSure system has the potential to address a significant unmet need in the market for more effective disinfection systems for hospitals, long term care facilities, and a number of applications beyond the healthcare marketplace. I look forward to leveraging my existing industry relationships and experience as an active member of the Board of Directors to support the team in reaching our growth objectives.”

About Medizone International, Inc.
Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the Company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International Announces Sales Agreement with Innovasource LLC

KALAMAZOO, MICH. April 24, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented disinfection of bacterial and viral pathogens, announced today that the Company has entered into a definitive agreement with Innovasource to provide sales support for Medizone’s commercial strategy for AsepticSure.

“We are very pleased to announce that Medizone International has reached an agreement to have Innovasource serve in a commissioned sales role in support of our commercial expansion. Innovasource has tremendous, long-standing relationships with some of the largest health systems and group purchasing organizations in the world,” said David Esposito, Chairman and CEO of Medizone International. “As we work together with Innovasource on a number of projects, we are excited about the customer base Innovasource has already brought to our attention. We look forward to delivering on the strong interest in AsepticSure that we are seeing from the Innovasource customer base.”

Under the sales agreement, Innovasource will promote AsepticSure to their current portfolio of customers. Medizone and Innovasource will coordinate support for sales presentations and product demonstrations to potential customers of AsepticSure. Specific terms of the agreement were not released.

“We are very pleased that Medizone recognized the value of our broad customer base and strong reputation of bringing valuable products and services to our customers. We look forward to adding AsepticSure to our portfolio as we already see strong demand for this innovative technology in a wide range of customer interactions,” said Andy Fay, Vice President of Business Development for Innovasource.

The AsepticSure disinfection system is a portable, affordable, easily operated system that demonstrates consistent disinfection of major pathogens in healthcare facilities.  The Company continues to expand commercial operations in key markets to address a major unmet need around the world.

About Medizone International, Inc.

The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the Company released its AsepticSure system for use in Canada and several other global markets. The Company is preparing to expand in the US market. AsepticSure received EPA approval in November of 2016 and the Company is currently working with the FDA to finalize the regulatory status of AsepticSure. Learn more at http://www.medizoneint.com

About Innovasource, LLC

Innovasource has an experienced team of product development, manufacturing, and marketing professionals focused on new, environmentally-sustainable product offerings for the customers they serve.

The Company was founded in 2007 by a seasoned team with over fifty years in regulated product experience. Innovasource operates in consumer and commercial channels, and is introducing a unique and proprietary line of hydrogen peroxide-based consumer products.

For consumer, commercial, and industrial applications, Innovasource improves the places where you work and live with innovative and effective products. Learn more at http://www.innovasource.com

Safe Harbor Statement

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the US and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

###

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 (269) 202-5020

E: [email protected]

For more information, visit: www.medizoneint.com

Medizone International Announces Next Steps on AsepticSure®

Medizone International prepares plans to submit AsepticSure for FDA approval as a medical device

Kalamazoo, Michigan, Friday, April 7, 2017 — Medizone International, Inc. (OTCQB: MZEI) announced that in a scheduled conference call late Thursday, April 6, 2017, with representatives of the U.S. Food and Drug Administration (“FDA”), the FDA had advised the Company that they believed AsepticSure should be classified as a medical device.  The FDA representatives recommended that the Company submit a Premarket Notification (“PMN” or “510(k)”) to the FDA and invited Company representatives to schedule follow up meetings to discuss the best approach for introduction of the AsepticSure technology into the U.S. market.  Section 510(k) of the Food, Drug and Cosmetic Act (“FDCA”) requires device manufacturers who must register, to notify FDA of their intent to market a medical device at least 90 days in advance. This is known as Premarket Notification – also called PMN or 510(k). This allows FDA to determine whether the device is equivalent to a device already placed into one of the three classification categories.  Specifically, medical device manufacturers are required to submit a premarket notification if they intend to introduce a device into commercial distribution for the first time or reintroduce a device that will be significantly changed or modified to the extent that its safety or effectiveness could be affected. Such change or modification could relate to the design, material, chemical composition, energy source, manufacturing process, or intended use.

In November 2016, Medizone received clearance from the U.S. Environmental Protection Agency (“EPA”) (Reg. No. 90607-3) to market AsepticSure ozone disinfectant formula for use for disinfection of non-porous surfaces in hospitals, clinics, hotels, sporting venues and in the food industry, long-term care facilities, and other critical infrastructures.  However, the FDA has indicated that it also believes it has jurisdiction over AsepticSure as a “medical device”.  The Company does not agree with the FDA’s position, however the Company has determined to work with its advisors on a response to the FDA to establish the most efficient route to gain regulatory approval of AsepticSure as a medical device under the FDCA.

The Company has informed the FDA that it will not market AsepticSure in the US under the previously announced EPA clearance until it has also obtained 510(k) clearance or other appropriate approvals from the FDA.

Medizone will continue to support commercial operations in markets outside the United States, which are not affected by this decision.  In addition to the EPA clearance, the AsepticSure technology has received market approval from regulators for use and distribution in Canada, New Zealand, and Chile, and is currently seeking approvals in other countries in South America, Europe and Asia.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

 

Contact:
John Pentony

Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
Email: [email protected]

 

http://www.medizoneint.com

 

 

Medizone International Expands Board of Directors to Support Executing on the Launch of AsepticSure in Key Global Markets

New Medizone Board Member, Dwayne Montgomery, will play critical role in the company’s growth plans.

Kalamazoo, Michigan, Thursday, April 6, 2017 —  Medizone International, Inc. (OTCQB: MZEI) announces the addition of Dwayne Montgomery to the Board of Directors. Medizone makes this move in support of expanding the commercial experience of the team and accelerating the growth of the company’s AsepticSure® hospital disinfection system.

“As Medizone International continues to move forward with our growth plans, it is important that we continue to build our team with talented commercial leaders to help the organization reach its potential in establishing the AsepticSure system as the new gold standard for disinfection across a wide range of commercial applications,” commented David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “As we execute on our global commercial plans for the AsepticSure system, we are pleased to announce that Dwayne Montgomery has joined our Board of Directors to help support our commercial strategy and business development initiatives.”

Mr. Montgomery brings a tremendous amount of global commercial experience as a senior executive in high growth segments of healthcare to his role on the board. His accomplished career spans 25+ years and is documented with deep knowledge and success in medical device and biotech executive management. His commercial expertise is backed with a proven track record of operational performance as well as business development success through mergers and acquisitions with both domestic and international organizations.

Mr. Montgomery has led companies through significant growth periods with varying size, including large, mid-cap, and start-up ventures. Most recently, Mr. Montgomery served as the President and Chief Executive Officer for Osiris Therapeutics, Inc., a market leading company focused on advancing regenerative medicine. He was also a member of Osiris Therapeutics’ Board of Directors. Most notably, Mr. Montgomery orchestrated Osiris Therapeutics’ strategic partnerships with both Arthrex and Stryker, leaders in their respective healthcare segments. Mr. Montgomery graduated with a Bachelor of Science degree in chemistry from the University of North Alabama and attained a Master of Business Administration degree from Belmont University.

Mr. Montgomery commented on joining the Board of Directors, “I am extremely honored to be joining the Board of Directors for Medizone International as we execute on our growth plans. I am impressed with this compelling and disruptive technology as well as its unique value-proposition. The AsepticSure system has the potential to be game-changing technology to address a significant unmet need in the market for more effective disinfection systems for hospitals, long-term care facilities, and a number of applications beyond the healthcare marketplace. I look forward to being a very active member of the Board of Directors to support the team in reaching our full commercial potential.”

About Medizone International, Inc.
The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets. With EPA approval in late 2016, the company is now prepared to expand into the U.S. market. Learn more at http://www.medizoneint.com/.

This Press Release may contain certain forward-looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

SOCIAL MEDIA:

Medizone International on Twitter:

https://twitter.com/asepticsure